
CLAIMS

1. A compound of Formula I:



Formula I

or pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof; wherein, RH independently represents omega 3 fatty acid, omega 6 fatty acid, alpha lipoic acid, R-lipoic acid.

2. The compound of claim 1, for use in treatment of xerostomia, dry mouth and dry mouth in Sjögren's syndrome.

3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3, which is formulated to treat xerostomia, dry mouth and/or dry mouth in Sjögren's syndrome, with an effective amount to be administered to the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.

5. Use of a compound of claim 1 in the manufacture of a medicament for the treatment of xerostomia, dry mouth and/or dry mouth in Sjögren's syndrome.

6. The use according to claim 5, wherein the medicament is to be administered by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.